drug_type
RELEVANT_DRUG
intervention_type
Biological - cellular therapy (CAR T cells)
drug_description
Donor-derived anti-CD33 chimeric antigen receptor (CAR) T-cell therapy using lentiviral-transduced allogeneic T cells from the patient’s original HLA-matched alloHCT donor; targets CD33 on AML cells to induce T-cell activation and cytolytic killing of CD33-positive leukemia and myeloid cells.
nci_thesaurus_concept_id
C202016
nci_thesaurus_preferred_term
Allogeneic Anti-CD33 CAR T-cells VCAR33
nci_thesaurus_definition
A preparation of allogeneic T-lymphocytes, derived from the same matched healthy donor who provided a stem cell transplant and transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) specific for the CD33 antigen, with potential immunomodulating and antineoplastic activities. Upon administration, allogeneic anti-CD33 CAR T-cells VCAR33 specifically recognize and kill CD33-expressing tumor cells. CD33 is expressed on normal non-pluripotent hematopoietic stem cells and is overexpressed on myeloid leukemia cells.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic donor-derived T cells are lentivirally engineered to express a CD33-specific chimeric antigen receptor; upon binding CD33 on AML and other myeloid cells, CAR signaling (CD3ζ/costimulation) activates the T cells to proliferate, release cytokines, and mediate cytolytic killing of CD33-positive cells.
drug_name
VCAR33
nct_id_drug_ref
NCT05984199